MHRA plans biggest overhaul of clinical trial regulation in 20 years

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said today it will introduce A series of new measures, with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK.

The Agency says these changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers.

Chief science and innovation officer at the MHRA, Marc Bailey, commented: “Our world-first COVID-19 approvals showed how important it is to ensure that regulation is flexible and agile. This overhaul of the clinical trials legislation will do just this – it will move us away from a one-size-fits-all approach to the regulation of clinical trials and help to streamline approvals by removing granular and duplicative regulatory requirements. This will make the UK one of the best countries in the world to conduct clinical research and, get innovative medicines to the people who need them faster.”